Ulcerative Colitis Drug Landscape 2026
Approved therapies, pipeline drugs, and clinical trial intelligence
New in 2025-2026
Overview
Ulcerative colitis (UC) is a chronic inflammatory bowel disease affecting the colon and rectum. Unlike Crohn's disease, UC inflammation is continuous (not patchy) and limited to the innermost lining of the colon. Affecting nearly 1 million Americans, UC causes symptoms including bloody diarrhea, urgency, and abdominal pain. Treatment has evolved from aminosalicylates and corticosteroids to targeted biologics and oral small molecules. The landscape includes TNF inhibitors, integrin antagonists, IL-23 blockers, JAK inhibitors, and S1P receptor modulators.
UC has the broadest array of approved advanced therapies among IBD indications, with S1P modulators ozanimod (Zeposia) and etrasimod (Velsipity) providing oral alternatives to injectable biologics. Despite these options, significant unmet need remains: up to 30% of UC patients eventually require colectomy, and steroid-free remission rates with current therapies rarely exceed 40-50%. The treatment paradigm is shifting toward treat-to-target strategies with endoscopic and histologic remission as endpoints, earlier escalation to advanced therapies, and biomarker-guided sequencing. Emerging targets include TL1A inhibitors, novel gut-selective molecules, and combination regimens pairing complementary mechanisms.
Historical Context
First formally described in 1859 by Sir Samuel Wilks at Guy's Hospital in London, who distinguished it from bacterial dysentery. Wilks performed autopsies on patients who died from chronic bloody diarrhea and noted inflammation limited to the colon's mucosal layer. The term 'ulcerative colitis' was later coined in 1888 by William Hale White. For decades, UC was treated only with supportive care until sulfasalazine was introduced in the 1940s, revolutionizing medical management.
Treatment Evolution
Year = first FDA approval for ulcerative colitis. Dashed = still in clinical development.
Mechanism Landscape
Current ulcerative colitis treatments span 6 distinct mechanism classes: IL-23 Blocker (3), TNF Blocker (3), S1P Modulator (2), JAK Inhibitor (2), Integrin Blocker (1), IL-12/23 Blocker (1). IL-23 Blocker leads with 3 approved drugs.
FDA-Approved Drugs
12 originators + 22 biosimilars12 approved therapies for ulcerative colitis across 6 mechanism classes: IL-23 Blocker (3), TNF Blocker (3), S1P Modulator (2), JAK Inhibitor (2), Integrin Blocker (1), IL-12/23 Blocker (1). Plus 22 biosimilars.
| Drug | Company | Mechanism | Ulcerative Colitis Approval |
|---|---|---|---|
| VELSIPITY ETRASIMOD ARGININE | Pfizer | S1P Modulator | 2023 |
| OMVOH MIRIKIZUMAB-MRKZ CD | Eli Lilly | IL-23 Blocker | 2023 |
| ZEPOSIA OZANIMOD HYDROCHLORIDE | Bristol-Myers Squibb | S1P Modulator | 2021 FDA: 2020 |
| SKYRIZI RISANKIZUMAB-RZAA CD | AbbVie | IL-23 Blocker | 2024 FDA: 2019 |
| RINVOQ UPADACITINIB CD | AbbVie | JAK Inhibitor | 2022 FDA: 2019 |
| TREMFYA GUSELKUMAB CD | Johnson & Johnson | IL-23 Blocker | 2025 FDA: 2017 |
| ENTYVIO VEDOLIZUMAB CD | Takeda | Integrin Blocker | 2014 |
| XELJANZ TOFACITINIB CITRATE | Pfizer | JAK Inhibitor | 2018 FDA: 2012 |
| STELARA USTEKINUMAB CD | Johnson & Johnson | IL-12/23 Blocker | 2019 FDA: 2009 |
| STARJEMZA biosimilar | BIO-THERA SOLUTIONS | IL-12/23 Blocker | 2025 |
| YESINTEK biosimilar | BION BIOLOGICS | IL-12/23 Blocker | 2024 |
| STEQEYMA biosimilar | Celltrion | IL-12/23 Blocker | 2024 |
| IMULDOSA biosimilar | ACRD BIO | IL-12/23 Blocker | 2024 |
| PYZCHIVA biosimilar | Samsung Bioepis | IL-12/23 Blocker | 2024 |
| SELARSDI biosimilar | ALVOTECH USA | IL-12/23 Blocker | 2024 |
| OTULFI biosimilar | Fresenius Kabi | IL-12/23 Blocker | 2024 |
| WEZLANA biosimilar | Amgen | IL-12/23 Blocker | 2023 |
| SIMPONI GOLIMUMAB | Johnson & Johnson | TNF Blocker | 2013 FDA: 2009 |
| HUMIRA ADALIMUMAB CD | AbbVie | TNF Blocker | 2012 FDA: 2002 |
| SIMLANDI biosimilar | ALVOTECH USA | TNF Blocker | 2024 |
| YUFLYMA biosimilar | Celltrion | TNF Blocker | 2023 |
| IDACIO biosimilar | Fresenius Kabi | TNF Blocker | 2022 |
| YUSIMRY biosimilar | HERUS BIOSCIENCES | TNF Blocker | 2021 |
| HULIO biosimilar | Viatris | TNF Blocker | 2020 |
| ABRILADA biosimilar | Pfizer | TNF Blocker | 2019 |
| HADLIMA biosimilar | Samsung Bioepis | TNF Blocker | 2019 |
| HYRIMOZ biosimilar | Novartis | TNF Blocker | 2018 |
| CYLTEZO biosimilar | Boehringer Ingelheim | TNF Blocker | 2017 |
| AMJEVITA biosimilar | Amgen | TNF Blocker | 2016 |
| REMICADE INFLIXIMAB CD | Johnson & Johnson | TNF Blocker | 2005 FDA: 1998 |
| ZYMFENTRA biosimilar | Celltrion | TNF Blocker | 2023 |
| AVSOLA biosimilar | Amgen | TNF Blocker | 2019 |
| RENFLEXIS biosimilar | Samsung Bioepis | TNF Blocker | 2017 |
| INFLECTRA biosimilar | Celltrion | TNF Blocker | 2016 |
22 biosimilars shown inline. Purple = biosimilar of the originator above.
Pipeline Snapshot
Active clinical trials for ulcerative colitis drugs across all development phases.
Key Companies
Major pharmaceutical companies active in ulcerative colitis drug development.
Showing top companies by approved drug count and pipeline activity.
Explore Further
Patent & Exclusivity Cliff
Emerging class: TL1A
3 Phase 3 programs targeting TL1A in ulcerative colitis. No approved drugs in this class yet - first pivotal readouts could reshape the treatment landscape.
Emerging drugs at unvalidated targets
See all emerging drugs →3 drugs in ulcerative colitis target a molecule with no FDA-approved drug — first-in-class candidates if Phase 3 reads out positive.
Active Phase 3 Trials
11 active Phase 3 programs from US, EU, and Japan-based sponsors across 6 mechanisms: Interleukin-23 Antagonist (3), TL1A (3), Janus Kinase Inhibitor (1), S1P1 (1), Integrin Receptor Antagonist (1), JAK1 (1). Novel classes not yet approved: TL1A.
| Drug | Sponsor | Trial | Est. Readout |
|---|---|---|---|
| Guselkumab | Johnson & Johnson | NCT04033445 | 2023-09 |
| Tulisokibart NEW | Merck | NCT06052059 | 2026-08 |
| Upadacitinib | AbbVie | NCT03006068 | 2027-07 |
| Etrasimod | Pfizer | NCT03950232 | 2029-06 |
| Intravenous (IV) infusions NEW | PolBiologics S.A. | NCT05771155 | 2025-09 |
| Duvakitug NEW | Sanofi | NCT07185009 | 2028-09 |
| Mirikizumab | Eli Lilly | NCT06937086 | 2028-04 |
| Afimkibart NEW | Roche | NCT06588855 | 2027-01 |
| Vedolizumab | Takeda | NCT05442567 | 2033-02 |
| Risankizumab | AbbVie | NCT07071519 | 2034-07 |
| tofacitinib | Pfizer | NCT04624230 | 2027-04 |
Stay Updated
Get notified when we publish new ulcerative colitis intelligence.
TheraRadar View
2026-04-20UC is anatomically more confined than Crohn's - continuous inflammation limited to the surface of the colon - which has made it a faster proving ground for new mechanisms. Patients now have the broadest advanced-therapy menu in IBD: TNF inhibitors, IL-23 blockers, integrin antagonists, JAK inhibitors, S1P modulators. Yet steroid-free remission rates still plateau around 40-50%, and up to 30% of patients eventually require colectomy. Every approved class suppresses inflammation; none addresses the underlying tissue damage.
TL1A changes that - it's the first mechanism targeting both the inflammatory cascade and the fibrosis that drives bowel damage. Three programs are in Phase 3 across IBD: Merck's tulisokibart, Roche's afimkibart, and Sanofi's duvakitug, with pivotal readouts expected through 2026-2027. Merck paid $10.8B for Prometheus in 2023 to acquire tulisokibart; that thesis is being validated now. Watch these readouts - they'll reset UC first-line positioning through 2030.